# Timothy Noyes

> Timothy Noyes is the President and CEO of Newleos Therapeutics, a Boston clinical-stage biotech that raised an oversubscribed $93.5M Series A to revive four neuropsychiatric compounds shelved by Roche. A Harvard-trained operator with three decades in biopharma, he has taken Proteon and Aerovate public, launched Renagel at GelTex/Genzyme, and built teams that carry molecules from bench to late-stage trials.

- **Role:** President & CEO at Newleos Therapeutics
- **Organizations:** Newleos Therapeutics, Aerovate Therapeutics, Proteon Therapeutics, Trine Pharmaceuticals, GelTex Pharmaceuticals, Genzyme, Merck & Co.
- **Nationality:** American
- **Education:** A.B., Harvard College, M.B.A., Harvard Business School
- **Known for:** Took two biotechnology companies (Proteon and Aerovate) public via IPO, Led the commercial launch of Renagel at GelTex Pharmaceuticals, Served as President of Genzyme's Renal Division

## Career timeline

- **Early career** — Joined Merck & Co. in commercial roles across the hypertension and heart failure group and managed care division, working on Vasotec and Prilosec
- **1990s** — Held management and leadership roles at GelTex Pharmaceuticals; led the commercial launch of Renagel for end-stage renal disease patients
- **Post-acquisition** — After Genzyme acquired GelTex, served as President of Genzyme's Renal Division and President of GelTex
- **2002** — Became Chief Operating Officer of Trine Pharmaceuticals
- **2006** — Appointed President & CEO of Proteon Therapeutics; led IPO and advanced PRT-201 from preclinical through Phase 3
- **2021** — Named CEO of Aerovate Therapeutics; led IPO and advanced an inhaled imatinib program for pulmonary arterial hypertension through a global Phase 2/3 trial
- **2025** — Appointed President & CEO of Newleos Therapeutics (October 2025), succeeding founding CEO David Donabedian

## Achievements

- Took two biotechnology companies (Proteon and Aerovate) public via IPO
- Led the commercial launch of Renagel at GelTex Pharmaceuticals
- Served as President of Genzyme's Renal Division
- Advanced Proteon's PRT-201 biologic from preclinical development through Phase 3 trials
- Guided Aerovate's lead pulmonary arterial hypertension program through a global Phase 2/3 trial

## Latest updates

- **2025-10** — Appointed President & CEO of Newleos Therapeutics, succeeding founding CEO David Donabedian, who moved to an advisory role

## Links

- Website: https://newleos.com
- LinkedIn: http://www.linkedin.com/in/timothy-noyes-75b624b9

---

Profile page: https://yespress.io/timothy-noyes
Published by YesPress — https://yespress.io
Last updated: 2026-06-04